UCB is committed to providing a unique portfolio of targeted treatments for patients with gMG.
RYSTIGGO Indication and Important Safety Information“By understanding the pathophysiology of gMG, we can see why ZILBRYSQ was designed to specifically target the complement cascade.”
Watch the video of Dr. Hannah Machemehl, an expert in gMG, discuss how ZILBRYSQ provides complement inhibition.
In gMG, pathogenic immunoglobulin G (IgG) autoantibodies attack key proteins, most commonly the acetylcholine receptor (AChR), in the neuromuscular junction (NMJ). This prevents acetylcholine (ACh) binding, reduces receptor density, and activates the complement system.1,2
ZILBRYSQ is a first-of-its-kind small peptide C5 inhibitor for the treatment of anti-AChR Ab+ gMG1,2
See how ZILBRYSQ, a C5 inhibitor, specifically targets the complement cascade, preventing the assembly and activity of the membrane attack complex.1,2
ZILBRYSQ is a first-of-its-kind macrocyclic peptide that specifically targets the complement cascade.
ZILBRYSQ binds to C5 with high affinity and specificity, preventing C5 cleavage into C5a and C5b by C5 convertase. This prevents the subsequent assembly and activity of the MAC, providing complement inhibition.
The precise mechanism through which ZILBRYSQ exerts therapeutic effects in gMG is unknown.1
References:
IMPORTANT SAFETY INFORMATION
INCLUDING BOXED WARNING
ZILBRYSQ, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis. Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early. Complete or update vaccination for meningococcal bacteria at least 2 weeks prior to the first dose of ZILBRYSQ, unless the risks of delaying therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination against meningococcal bacteria in patients receiving a complement inhibitor. Patients receiving ZILBRYSQ are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected. ZILBRYSQ is available only through a restricted program called ZILBRYSQ REMS. ZILBRYSQ is contraindicated for initiation in patients with unresolved serious Neisseria meningitidis infection. Additional important warnings and precautions associated with ZILBRYSQ include an increased susceptibility to infections and pancreatitis and pancreatic cysts. The most common adverse reactions (≥10%) were injection site reactions, upper respiratory tract infection, and diarrhea.
